Masahiko Tanabe, MD, PhD


Associate Professor
Department of Breast Oncology
Juntendo University School of Medicine
2-1-1 Hongo Bunkyo-ku
Tokyo 113-8421, Japan

Biography

Dr. Tanabe, Medicine Doctor (Ph.D.-medicine), now is an Associate professor of the Department of Breast Oncology at Juntendo University School of Medicine. He is a surgical oncologist for breast cancer as well as a certified specialist in medical genetics. He got his Medicine Doctor s degree (Ph.D.) at the University of Tokyo. Currently. Dr. Tanabe is delighted to collaborate with the Cancer Studies and Molecular Medicine -Open Journal (CSMMOJ). He can contribute to review manuscripts on epigenetic biology and clinical field of breast cancer.

Research Interest

His research interest includes: Treatment of metastatic breast cancer which is resistant after multiple treatment, and he is continuously exploring epigenetic marks on estrogen receptor target genes which are associated with progression of breast cancer.

Scientific Activities

Publications

1. Himuro T, Horimoto Y, Arakawa A, Tanabe M, Saito M. Ki67 Heterogeneity in Estrogen Receptor-Positive Breast Cancers: Which Tumor Type Has the Most Heterogeneity?. Int J Surg Pathol. 2015.
2. Fukuda T, Tanabe M, Kobayashi K, et al. Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine. Springerplus. 2015; 4: 376. doi:10.1186/s40064-015-1159-4
3. Horimoto Y, Arakawa A, Tanabe M, et al. Menstrual cycle could affect Ki67 expression in estrogen receptor-positive breast cancer patients. J Clin Pathol. 2015. doi:10.1136/jclinpath-2015-203085
4. Sakai T, Nishimura S, Ogiya A, et al. Four types of ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery: classification of IBTR based on precise pathological examination. Pat-hol Int. 2015; 65(3): 113-118. doi:10.1111/pin.12253
5. Horimoto Y, Arakawa A, Tanabe M, et al. Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer. BMC Cancer. 2014; 14: 550. doi:10.1186/1471-2407-14-550
6. Nakayama Y, Ito Y, Tanabe M, Takahashi S, Hatake K. A combination of aprepitant, palonosetron, and dexamethasone prevents emesis associated with anthracycline-containing regimens for patients with breast cancer. A retrospective study. Breast Cancer. 2015; 22(2): 177-84. doi:10.1007/s12282-013-0472-4
7. Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society et al. Repeat lumpectomy for ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery: the impact of radiotherapy on second IBTR. Breast Cancer. 2014; 21(6):754-760. doi:10.1007/s12282-013-0454-6
8. Nakayama Y, Ito Y, Tanabe M, Takahashi S. Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer. Case Rep Oncol. 2013; 6(1): 50-54. doi:10.1159/000346839
9. Nishimura S, Tanabe M, Morizono H, et al. Clear cell sarcoma of the neck which metastasized to the mammary gland. Case Rep Oncol. 2013; 6(1): 55-61. doi:10.1159/000345843
10. Uehiro N, Horii R, Iwase T, et al. Validation study of the UICC TNM classification of malignant tumors, seventh edition, in breast cancer. Breast Cancer. 2014; 21(6): 748-753. doi:10.1007/s12282-013-0453-7
11. Ishitobi M, Okumura Y, Arima N, et al. Breast cancer subtype and distant recurrence after ipsilateral breast tumor recurrence. Ann Surg Oncol. 2013; 20(6): 1886-1892. doi:10.1245/s10434-012-2825-1.
12. Ito S, Nakamura S, Kimura S, et al. Epigenetic Silencing of Core Histone Genes by HERS in Drosophila. WI Cell. 2012; 45(4): 494-504. doi:10.1016/j.molcel.2011.12.02
13. Sawatsubashi S, Murata T, Lim J, et al. A histone chaperone, DEK, transcriptionally coactivates a nuclear receptor. Genes Dev. 2010; 24(2): 159-70. doi:10.1101/gad.185741
14. Nakamura S, Ito S, Sawatsubashi S, et al. BTB protein, dKLHL18/CG3571, serves as an adaptor subunit for a dCul3 ubiquitin ligase complex. Genes Cells. 2009; 14(8): 965-973. doi:10.1111/j.1365-2443.2009.01323.x
15. Suzuki E, Zhao Y, Ito S, et al. Aberrant E2F activation by polyglutamine expansion of androgen receptor in SBMA neu rotoxi city. Proc Natl Aced Sci USA. 2009; 106(143818-22. doi:10.1073/pnas.0809819106
16. Tanabe M, Ito Y, Tokudome N, et al. Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes. Breast Cancer. 2009; 16(4): 301-306. doi:10.1007/s12282-009-0093-0
17. Zhao Y, Takeyama K, Sawatsubashi S, et al. Corepressive action of CBP on androgen receptor transactivation in pericentric heterochromatin in a Drosophila experimental model system. Mal Cell Biol. 2009; 29(4): 1017-1034.
18. Murata T, Suzuki E, Ito S, et al. RNA-binding protein hoip accelerates polyQ-induced neurodegeneration in Drosophila. Biosci Biotechnol Biochem. 2008; 72(9): 2255-2261.
19. Kimura S, Sawatsubashi S, lto S, et al. Drosophila arginine methyltransferase 1 (DART1) is an ecdysone receptor co-repressor. Biochem Biophys Res Commun. 2008; 371(4): 889-893. doi:10.1016/j.bbrc.2008.05.00
20. Tokudome N, Sakamoto G, Sakai T, et al. A case of carcinosarcoma of the breast. Breast Cancer. 2005; 12(2): 149-153.
21. Yoshimoto M, Tada K, Hori H, et al .Improvement in the prognosis of Japanese breast cancer patients from 1946 to 2001–an institutional review. Jpn J Clin Oncol. 2004; 34(8): 457-462.
22. Tamura M, Tada T, Tsuji H, et al. Clinical study on the metastasis to the eyes from breast cancer. Breast Cancer. 2004; 11(1): 65-68.